Focused Wealth Management’s AbbVie ABBV Stock Holding History

Focused Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,500	Closed	-$6K	–	683
2016 Q4	$6K	Buy	+10,500	New	+$641K	﹤0.01%	524

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Focused Wealth Management's ABBV Position: Q2 2026 in Review

Focused Wealth Management increased its AbbVie (ABBV) stake by 3.9% in Q2 2026, buying an estimated $77.9K and bringing the position to 9,724 shares worth $2.45M. The position accounts for 0.21% of the portfolio, ranked #55.

Focused Wealth Management first reported a position in ABBV in Q3 2013 and has held it in 52 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Focused Wealth Management held 9,724 shares of AbbVie worth $2.45M as of Q2 2026.
Focused Wealth Management bought 362 AbbVie shares in Q2 2026, an estimated $77.9K.
AbbVie made up 0.21% of Focused Wealth Management's portfolio in Q2 2026, its #55 holding.
Focused Wealth Management first reported a position in AbbVie in Q3 2013 and has held it in 52 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Focused Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.